Granted Patent
B2
US 12,589,151 · App. 17/297,380 · Granted Mar 31, 2026
T cell modification
Assignee:
USWM CT, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a modified T cell or population of modified T cells comprising a heterologous recombinant T cell receptor (TCR) and heterologous recombinant co-receptor, additionally provided are methods of producing the modified T cell or population of modified T cells and their use in the treatment of cancer.
Claims (8)
1 . An isolated modified T cell or a population of isolated modified T cells comprising a heterologous homodimeric CD8αco-receptor and a heterologous T cell receptor (TCR) that binds MAGE-A4.
2 . The modified T cell or the population of modified T cells according to claim 1 , wherein the CD8α co-receptor comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1.
3 . The modified T cell or the population of modified T cells according to claim 1 , wherein the TCR binds a cancer or a tumour antigen or a peptide thereof and/or is an affinity enhanced TCR.
4 . The modified T cell or the population of modified T cells according to claim 1 , wherein the TCR comprises an a chain amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 3.
5 . The modified T cell or the population of modified T cells according to claim 4 , wherein the TCR further comprises a β chain amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 5.
6 . The modified T cell or the population of modified T cells according to claim 1 , wherein the modified T cell or cells are CD4+.
7 . The modified T cell or the population of modified T cells according to claim 1 , wherein the TCR comprises an a chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a β chain variable region comprising the amino acid sequence of SEQ ID NO:8.
8 . The modified T cell or the population of modified T cells according to claim 1 , wherein the TCR comprises an α chain variable region (Vα) comprising complementarity determining regions (CDRs) Vα CDR1, Vα CDR2, and Vα CDR3 and a β chain variable region (Vβ) comprising CDRs Vβ CDR1, Vβ CDR2, and Vβ CDR3, wherein the Vα CDR1 comprises the amino acid sequence of SEQ ID NO: 9 , the Vα CDR2 comprises the amino acid sequence of SEQ ID NO: 10, the Vα CDR3 comprises the amino acid sequence of SEQ ID NO: 11, the Vβ CDR1 comprises the amino acid sequence of SEQ ID NO: 12, the Vβ CDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the Vβ CDR3 comprises the amino acid sequence of SEQ ID NO: 14.
Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 28, 2025
From: ADAPTIMMUNE LIMITED
To: USWM CT, LLC
Reel/Frame 072695/0013 →
RELEASE OF SECURITY INTEREST
Recorded Aug 28, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: TCR2 THERAPEUTICS INC.; ADAPTIMMUNE LIMITED
Reel/Frame 072700/0192 →
SECURITY INTEREST
Recorded Jul 31, 2025
From: USWM, CT LLC
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071900/0335 →
RELEASE OF SECURITY INTEREST
Recorded Jul 31, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: TCR2 THERAPEUTICS INC.; ADAPTIMMUNE LIMITED
Reel/Frame 072313/0252 →
SECURITY INTEREST
Recorded May 14, 2024
From: TCR2 THERAPEUTICS INC.; ADAPTIMMUNE LIMITED
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 067410/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 2, 2021
From: MELCHIORI, LUCA; BREWER, JOANNA
To: ADAPTIMMUNE LIMITED
Reel/Frame 057991/0455 →
Priority Claims (1)
GB 1819540
· Nov 30, 2018
· national
Continuity (1)
References Cited (102)
US 7388072B2
· Zhang et al.
· 2008
[cited by applicant]
US 7521197B2
· Savage
· 2009
[cited by applicant]
US 7666604B2
· Jakobsen et al.
· 2010
[cited by applicant]
US 20050118676A1
· Qi et al.
· 2005
[cited by applicant]
US 20120009162A1
· Yasukawa
· 2012
[cited by applicant]
US 20140378389A1
· Robbins et al.
· 2014
[cited by applicant]
US 20170333480A1
· Cooper et al.
· 2017
[cited by applicant]
US 20190135892A1
· Tribble et al.
· 2019
[cited by applicant]
US 20190144521A1
· Tribble et al.
· 2019
[cited by applicant]
US 20210040558A1
· Schumacher
· 2021
[cited by examiner]
CN 101287831A1
· 2008
[cited by applicant]
CN 104853766A
· 2015
[cited by applicant]
CN 105163765A
· 2015
[cited by applicant]
CN 106749620A
· 2017
[cited by applicant]
CN 107074970A
· 2017
[cited by applicant]
CN 108366995A
· 2018
[cited by applicant]
CN 110325633A
· 2019
[cited by applicant]
CN 110582299A
· 2019
[cited by applicant]
CN 110951690A
· 2020
[cited by applicant]
CN 111315402A
· 2020
[cited by applicant]
CN 13166778
· 2021
[cited by examiner]
CN 113166778A
· 2021
[cited by applicant]
EP 1930433
· 2008
[cited by applicant]
JP 2007527191A
· 2007
[cited by applicant]
JP 2012531904A
· 2012
[cited by applicant]
JP 2013126415A
· 2013
[cited by applicant]
JP 2013541332
· 2013
[cited by applicant]
JP 2019511222A
· 2019
[cited by applicant]
KR 102349677
· 2022
[cited by applicant]
KR 102523449
· 2023
[cited by applicant]
RU 2355703
· 2009
[cited by applicant]
WO WO2000020445
· 2000
[cited by applicant]
WO WO02094981
· 2002
[cited by applicant]
WO WO2002102852
· 2002
[cited by examiner]
WO WO2004074322
· 2004
[cited by applicant]
WO 2011001152A1
· 2011
[cited by applicant]
WO WO2012038055
· 2012
[cited by applicant]
WO WO2012054825A1
· 2012
[cited by applicant]
WO WO2013039889A1
· 2013
[cited by applicant]
WO WO2016055785A1
· 2015
[cited by applicant]
WO 2016054086A1
· 2016
[cited by applicant]
WO 2016073755A2
· 2016
[cited by applicant]
WO WO2016191756
· 2016
[cited by applicant]
WO 2017133175A1
· 2017
[cited by applicant]
WO 2017158103A1
· 2017
[cited by applicant]
WO WO2017174823
· 2017
[cited by examiner]
WO 2018055140A1
· 2018
[cited by applicant]
WO 2018170338A2
· 2018
[cited by applicant]
WO 2019204662A1
· 2019
[cited by applicant]
Chua I.C., CD8 co-receptor modifications to enhance T cell immunotherapy, 2013, Thesis, pp. 1-193.
[cited by examiner]
Brett et al, CN 13166778 translation pp. 1-31.
[cited by examiner]
Hiasa et al “Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) αβ genes transduced to CD8+ T cells” Gene Therapy 2008, vol. 15, pp. 695-699.
[cited by applicant]
Lyons et al “Influence of Human CD8 on Antigen Recognition by T-Cell Receptor-Transduced Cells” Cancer Res, 2006, vol. 66, No. 23, pp. 11455-11461, doi: 10.1158/0008-5472.CAN-06-2379.
[cited by applicant]
Aggen et al. “Single-Chain VaVβ T Cell Receptors Function Without Mispairing With Endogenous TCR Chains”, Gene Ther. Apr. 2012; 19(4): 365-374 (Year: 2012).
[cited by applicant]
Anonymous: EMBL CDS: BAS03571: Sequence: UPI000676CA51 (Aug. 1, 2015) Retrieved from Internet URL http://www.uniprotorg/uniparcJUP!000676CA51. Retrieved on Sep. 6, 2017.
[cited by applicant]
Anonymous: EMPB CDS: BAF94626—Sequence: UPI000'1614056 (Dec. 30, 2007) Retrieved from Internet URL http://www. uniprotorgilmiparc/UPI0001614056. Retrieved on Sep. 6, 2017.
[cited by applicant]
Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions”, Biomolecular Research Institute, Research in Immunology, 1994, vol. 245, No. 1, pp. 33-36.
[cited by applicant]
Cordoba et al., “The Large Ectodomains of CD45 and CD148 Regulate Their Segregation from the Inhibition of Ligated Ir-Cell Receptor”, Blood, May 23, 2013, vol. 121, No. 21, pp. 4295-4302.
[cited by applicant]
De la Hera et al., “Structure of the T Cell Antigen Receptor {TCR) Two CD3e Subunits in a Functional TCR/CD3 Complex”, J_ Exp_ Med., vol. 173, Jan. 1991, pp. 7-17.
[cited by applicant]
Duffour et al., “A MAGE-A4 Peptide Presented by HLA-A2 is Recognized by Cytolytic T Lymphocytes”, Eur. J. mmunoL 1999, vol. 29, pp. 3329-3337.
[cited by applicant]
English translation of Chinese Office Action issued Jun. 1, 2021, in corresponding Chinese Appln. No. 017800317102.
[cited by applicant]
Fidler IJ. “Biological heterogeneity of cancer: implication to therapy”, Hum Vaccin Immunother. Aug. 2012;8(8):1141-2. (Year: 2012.
[cited by applicant]
Fujiwara-Kuroda et al. “Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status”, Int J Oneal. Aug. 2018;53(2):713-724. (Year: 2018).
[cited by applicant]
Gasser, et al., “Antibody Production with Yeast and Filamentous Fungi: On the Road to Large Scale?”, Biotechnol. Lett (2007) vol. 29, No. 2, p. 201-212.
[cited by applicant]
Hillig, et al., “High-resolution Structure of HLA-A*0201 in Complex with a Tumour-specific Antigenic Peptide Encoded DY the MAGE-A4 Gene”, J_ Mal_ Biol. (2001) vol. 310, p. 1167-1176_.
[cited by applicant]
Holler, et al., “Quantitative Analysis of the Contribution of TCR/pepMHC Affinity and COB to T Cell Activation”, Immunity (Feb. 2003) vol. 18, p. 255-264.
[cited by applicant]
Ikeda et al. “In vivo persistence of adoptively transferred TCR gene-transduced lymphocytes with anti-tumor reactivity in patients with MAGE-A4 expressing esophageal cancer”, J Immunother Cancer. 2013; 1 (Suppl 1 ): 03.…
[cited by applicant]
Jia, et al., “Identification of Two Novel HLA-A*0201-Restricted CTL Epitopes Derived from MAGE-A4”, Clinical and Developmental Immunology, vol. 2010, Artilce 567594, 7 pages, 2010.
[cited by applicant]
The Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on Oct. 19, 2020]. <URL: https://www.merckmanuals.com/professional/hematology- and- oncology…
[cited by applicant]
Ozawa, et al., “Comprehensive analysis of the functional TCR repertoireat the single-cell level”, Biochemical and Biophysical Research Communications 367 (2008) 820-825.
[cited by applicant]
Pakula, et al., “Genetic Analysis of Protein Stability and Function”, Annu. Rev. Genet {1989) vol. 23, p. 289-310.
[cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc Natl Acad Sci USA. Mar. 1982; 79(6): 1979-1983. (Year: 1982).
[cited by applicant]
Safdari et al., “Antibody Humanization Methods—A Review and Update”, Biotechnology and Genetic Engineering Reviews, vol. 29, No. 2, pp. 175-186, 2013.
[cited by applicant]
Wahl, et al. “ HLA Class I Molecules Reflect an Altered Host Proteome After Influenza Virus Infection”, Human Immunology (2010) vol. 71, p. 14-22.
[cited by applicant]
Hiasa et al., “Rapid αξ TCR-mediated responses in γδ T cells transduced with cancer-specific TCR genes”, Gene Therapy (2009) 16, pp. 620-628.
[cited by applicant]
Willemsen et al., “Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCRαξ gene transfer requires CD8α”, Gene Therapy (2005) 12, pp. 140-146.
[cited by applicant]
English Translation of Japanese Office Action dated Mar. 12, 2024, for Japanese Patent Application No. 2021-530124, 7 pages.
[cited by applicant]
English Translation of Japanese Office Action dated May 21, 2021, for Japanese Patent Application No. 2018-552872, 4 pages.
[cited by applicant]
English Translation of Korean Office Action dated Aug. 8, 2021, for Korean Patent Application No. 10-2018-7032168, 7 pages.
[cited by applicant]
English Translation of Chinese Office Action dated Jul. 10, 2024, for Chinese Patent Application No. 201980089522.4, 8 pages.
[cited by applicant]
Anderson et al., “Abstract 2313: Enhanced activity of second-generation MAGE-A4 Spear T-cells through co-expression of a CDS,” published Jul. 2019, Cancer Research, 4 pages.
[cited by applicant]
Willemsen et al., “CD8a Coreceptor to Improve TCR Gene Transfer to Treat Melanoma: Down-Regulation of Tumor-Specific Production of IL-4, IL-5, and IL-10,” The Journal of Immunology, 2006, 177 (2): 991-998.
[cited by applicant]
Xue et al., “Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CDS mediate efficient tumor rejection in vivo,” Oncolmmunology 2:1, e22590; Jan. 2013 (Year: 2013).
[cited by applicant]
Robbins et al., “Single and Dual Amino Acid Substitutions in TCR CD Rs can Enhance Antigen-Specific T Cell Functions,” J Immunol (2008) 180 (9): 6116-6131. (Year: 2008).
[cited by applicant]
Chuanlin et al., “Current Medical Immunology,” Shanghai Medical University Press, p. 36, published on Oct. 31, 1998, 4 pages with English translation.
[cited by applicant]
Kessels et al., “Generation of T Cell Help through a MHC Class I-Restricted TCR,” The Journal of Immunology, 2006, 177 (2): 976-982.
[cited by applicant]
Cole et al., “CD8: Adhesion Molecule, Co-Receptor and Immuno-Modulator,” Cellular & Molecular Immunology, 2004, 1 (2): 81-88.
[cited by applicant]
McNicol et al., “CD8α/α homodimers fail to function as co-receptorfor a CD8-dependent TCR,” European Journal of Immunology, 2007, 37: 1634-1641.
[cited by applicant]
Laugel et al., “Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties,” The Journal of Biological Chemistry, 2007, 282 (33):…
[cited by applicant]
Morris et al., “A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection,” PNAS, 2005, 102 (22): 7934-7939.
[cited by applicant]
Bethune Michael T., et al., “Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules11”, Proceedings of the National Academy of Sciences of the United States of America, …
[cited by applicant]
Soto, Carolina M., et al., “MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR11”, Cancer Immunology Immunotherapy, vol. 62, No…
[cited by applicant]
Zhou et al: “T-cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing” Blood,2012, vol. 120, No. 22,pp. 4334-4342, DOI.
[cited by applicant]
Dorrie et al: “Human Adenovirus specific γ/δ and CD8+ cells generated by T-Cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation” PLoS One,2014, vol. 9, No. 10,e109944 (pp. …
[cited by applicant]
Bajwa et all “440. Reprogramming CD4 T Cells into Cytotoxic CD8 Cells by Forced Expression of CD8αβ and Class I Restricted T Cell Receptors”, Molecular Therapy, May 2018, vol. 26, No. 5S1,p. 20.
[cited by applicant]